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The gut-brain axis (GBA) refers to the complex interactions between the gut microbiota and the nervous, immune, and
endocrine systems, together linking brain and gut functions. Perturbations of the GBA have been reported in people with
multiple sclerosis (pwMS), suggesting a possible role in disease pathogenesis and making it a potential therapeutic
target. While research in the area is still in its infancy, a number of studies revealed that pwMS are more likely to exhibit
altered microbiota, altered levels of short chain fatty acids and secondary bile products, and increased intestinal
permeability. However, specific microbes and metabolites identified across studies and cohorts vary greatly. Small clinical
and preclinical trials in pwMS and mouse models, in which microbial composition was manipulated through the use of
antibiotics, fecal microbiota transplantation, and probiotic supplements, have provided promising outcomes in preventing
CNS inflammation. However, results are not always consistent, and large-scale randomized controlled trials are lacking.
Herein, we give an overview of how the GBA could contribute to MS pathogenesis, examine the different approaches
tested to modulate the GBA, and discuss how they may impact neuroinflammation and demyelination in the CNS.
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Introduction
The gut-brain axis (GBA) is the bidirectional communication 
between the CNS and the gastrointestinal system, linking brain and 
gut functions. It involves a complex network of interactions between 
the endocrine, immune, autonomic, and enteric nervous systems. 
The gut microbiota and the intestinal barrier, key players in the GBA, 
have recently attracted much interest due to their emerging role in 
mediating health and disease and potential use as therapeutic tar-
gets. The gut microbiota affects many aspects of brain development 
and function, including microglia and astrocyte maturation and 
polarization, blood-brain barrier (BBB) formation and permeability, 
neurogenesis, and myelination (1–7). GBA disruption may participate 
in the pathophysiology of several brain disorders, including multiple 
sclerosis (MS) (6, 8–10). Numerous reports in the last decade have 
focused on the role of the gut microbiota and intestinal barrier in MS 
and its main animal model, experimental autoimmune encephalo-
myelitis (EAE). However, a great deal of controversy exists surround-
ing the extent and the exact mechanisms through which altered GBA 
may influence the development of CNS inflammation, demyelin-
ation, and axonal loss. In this Review, we summarize current liter-
ature exploring the GBA’s role in MS and relevant animal models, 
focusing on current and potential therapeutic strategies targeting the 
GBA to improve disease in people with MS (pwMS).
The GBA in MS and its animal models
MS is a multifactorial disease arising from a complex interplay 
between genetic and environmental factors (11, 12). Alterations in 
gut microbiota composition (13–18), gut-derived products (19–21), 
intestinal permeability (22–24), and endocrine (25) and enteric 
nervous system functions (26) have been described in pwMS. The 
consequences of these disruptions are linked directly or indirectly 
to activation of the immune system against CNS self-components 
and development of CNS autoimmunity. These pathophysiologi-
cal aspects have started to be characterized in MS animal models, 
whereas mechanistic studies in pwMS are still scarce. Below, we 
will consider the role of the different GBA components (gut micro-
biota, intestinal barrier, and immune, autonomic, and endocrine 
systems) in CNS autoimmunity and evidence of their alterations 
in pwMS and in MS animal models.
The gut microbiota and products of bacterial 
metabolism
Previous studies have described perturbations in both gut micro-
biota composition and gut-related metabolic pathways in pwMS 
(13–21, 27). Differences in single taxonomic units are more widely 
reported than large-scale gut microbiota differences when com-
paring pwMS with healthy controls (HCs) (13, 14, 16, 28). Unfor-
tunately, results across studies lack consistency. Sample size, sub-
ject heterogeneity, study design, type of controls, geographical 
location, sequencing platforms, and regions of 16S rRNA gene 
sequencing may all contribute to lack of reproducibility (29). 
Despite this limitation, certain taxa are consistently noted as dif-
ferentially represented in pwMS compared with HCs. In a study 
involving 34 monozygotic twins discordant for MS, the genus 
Akkermansia was overrepresented in the untreated MS twin com-
pared with the healthy twin (16). Two other studies confirmed 
these results, also demonstrating an increase in Acinetobacter and 
Methanobrevibacter and a decrease in Parabacteriodes and Butyr-
icimonas genera (13, 17). Other consistent changes observed across 
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tory effects (20, 38, 39). Emerging evidence indicates that SCFAs 
can cross the BBB and control neuroimmune homeostasis (40). 
SCFAs were significantly decreased in people with secondary pro-
gressive MS with long disease duration compared with HCs (20). 
Propionate levels were reduced in serum and stool samples of two 
different cohorts of pwMS across different disease subtypes com-
pared with HCs. This alteration was concomitant to a reduction in 
the abundance of SCFA-producing gut bacteria, decreased Tregs, 
and increased IL-17–producing T cell proportions in blood (21). 
In contrast, plasma levels of acetate were reported to be higher in 
a cohort of pwMS compared with HCs and correlated with both 
Expanded Disability Status Scale (EDSS) score and proportions of 
IL-17–producing CD8+ cells (41).
Primary bile acids are mainly produced by the liver and sub-
sequently modified by intestinal microbes to produce secondary 
bile acids. Bile acids and their metabolites can modulate glial and 
myeloid cell activation within the CNS via cell receptors and may 
play a neuroprotective role (42). Circulating levels of bile acid 
metabolites are altered in pediatric and adult cohorts of pwMS, 
and in EAE mice (19, 43); indeed, Bhargava and colleagues identi-
fied dysregulation of secondary bile acid metabolism in pwMS (19). 
multiple studies included a reduced abundance of Bacteroidace-
ae family, Faecalibacterium, Clostridium species, and Prevotella 
strains (15, 27, 30, 31). Clostridium species were shown to promote 
Treg accumulation in the colon, with a consequent immunomodu-
latory effect (32). Polysaccharide A, from the capsule of the human 
commensal Bacteroides fragilis, has been described as a powerful 
immune cell activator that induced clonal CD4+ T cell expansion 
(33) and IL-10 secretion in T and B cells (34, 35). Whether these 
gut microbiota alterations in MS could contribute to disease 
pathogenesis or are just a consequence remains unknown. Sup-
porting a real pathogenic role is the finding that gut microbiota or 
gut-derived molecules obtained from pwMS could modulate EAE 
when transferred into mice (16, 17, 36).
Microbial metabolites are altered in pwMS. Pathways most 
commonly found modulated in the gut microbiota of pwMS 
include carbohydrate and lipid metabolism and short chain fatty 
acid (SCFA) and bile acid synthesis (14, 37). SCFAs, including ace-
tate, propionate, and butyrate, are produced by microbial fermen-
tation of dietary fiber in the colon, where they maintain intestinal 
barrier integrity and dampen intestinal inflammation (38). They 
are then absorbed by the host and exert systemic immunomodula-
Figure 1. Gut-immune system interactions. The gut microbiota interacts with both the enteric nervous system and the immune system through multiple 
mechanisms. Bacterial-derived metabolites (i.e., SCFAs and bile acids) or membrane components (i.e., LPS and polysaccharide A [PSA], the latter associated 
with the membrane of Bacteroides fragilis) can modulate the maturation and development of Th17 cells and Tregs and can regulate intestinal motility. Tight 
junctions on epithelial cells play a critical role in controlling intestinal permeability, and their function can be regulated by epithelial molecules (i.e., IgA and 
zonulin [HP2]) that can also impact gut microbiome composition. Disease-modifying treatments and vitamin D are known to act on gut permeability, includ-
ing T cell migration through intestinal vessels (i.e., effects of natalizumab, a monoclonal antibody widely used to treat MS). The effector mechanisms depicted 
in the figure could act differently in the small intestine versus the colon. For instance, SCFAs are preferentially produced by fermentation of dietary fibers 
in the colon, where they can influence Treg differentiation. In contrast, segmented filamentous bacteria (SFB) are commensal bacteria attached to the ileal 
epithelium that in mice have been shown to promote the differentiation of Th17 cells. 5-HT, 5-hydroxytryptamine; A. muciniphila, Akkermansia muciniphila; 
DMF, dimethyl fumarate; ENS, enteric nervous system.
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The three major TJ proteins are occludin, claudins, and junctional 
adhesion molecule proteins (48). TJ barriers are dynamic, and TJ 
protein expression is influenced by many factors, including age, 
microbial antigens, and certain cytokines such as TNF-α (49–52). 
In human small intestine, the secreted protein zonulin or hapto-
globin 2 precursor (HP2) is a master regulator of TJ protein expres-
sion, and its presence triggers TJ disassembly (47). Heightened 
intestinal permeability or “leaky gut” can cause unregulated pas-
sage of luminal contents into the host (47) and subsequent activa-
tion of immune cells by otherwise nonimmunogenic commensal 
microbes. Indeed, a leaky gut is a common hallmark of inflamma-
tory disease, and HP2 overexpression has been observed in multi-
ple autoimmune diseases, including MS (23, 47, 53).
A recent pilot study demonstrated that people with relaps-
ing-remitting MS (RRMS) are more likely to have compromised 
intestinal permeability (54). Plasma from pwMS displays higher 
biomarkers of intestinal barrier integrity, particularly HP2 (55). 
These changes correlate with BBB disruption, as measured by MRI 
(55). Interestingly, HP2 is thought to pass into the bloodstream to 
reach the BBB, providing a possible mechanistic explanation for 
how intestinal barrier integrity may influence BBB permeability 
and subsequently CNS inflammation (24, 55). However, increased 
BBB permeability by HP2 was demonstrated only in vitro (24).
Consistent with altered gut barrier integrity, pwMS have 
increased low-grade bacterial translocation as measured by 
detectable plasma levels of LPS (23, 47) and increased LPS-bind-
ing protein, which was also reported in EAE (55, 56). More recent-
ly, peptidoglycan, an abundant bacterial cell wall component, was 
detected in brain tissue lesions of pwMS (57, 58). However, wheth-
er its presence in blood is indicative of inflammatory disease is not 
understood since peptidoglycan was previously detected in the 
serum of healthy patients (57).
As in pwMS, EAE mice develop increased intestinal barrier 
permeability accompanied by morphological changes in the small 
intestine (22, 59). These intestinal alterations were observed after 
adoptive transfer of myelin oligodendrocyte glycoprotein–reactive 
(MOG-reactive) CD4+ T cells, suggesting that circulating autoreac-
tive T cells are critical to induce gut barrier alterations (22). Further, 
loss of intestinal barrier integrity worsened at EAE day 15 versus day 
7, suggesting that EAE progression promotes gut permeability (22).
The intestinal tract’s mucus lining is a critical physical barrier 
between the host and microbes (60), composed of glycosylated pro-
teins, collectively termed mucins, and electrolytes, lipids, and IgA 
(60). Mucin loss or excessive mucin degradation has been demon-
strated to increase gut permeability and thereby create an inflam-
matory state. Certain microbes, such as A. muciniphila, are known to 
degrade the mucus layer and thereby alter the local immune milieu 
(61). As outlined above, A. muciniphila is increased in both pwMS 
and EAE mice (13, 62). While a strong correlation exists between 
the presence of mucus-degrading bacteria and MS, its contribution 
to disease pathogenesis remains unknown. Mucus-degrading bac-
teria may facilitate the inflammatory effects of other microbes and 
therefore only wreak havoc when combined with certain immuno-
genic bacteria (63). In contrast, a study in which miR-30d transfer 
promoted Akkermansia abundance found that EAE symptoms were 
suppressed via Treg promotion (36). Consistent with this, a recent 
study associated Akkermansia with lower disability in pwMS, and 
Mice supplemented with the secondary bile acid tauroursodeoxy-
cholic acid (TUDCA) had lower EAE disease burden compared with 
untreated mice, indicating this bacterial product’s protective role.
The intestinal barrier
The intestinal barrier’s critical role in absorbing nutrients and 
metabolites, while preventing the permeation of intestinal 
microbes, toxins, and other antigens (44), is achieved through 
the actions of key components: the intestinal immune system; the 
epithelial layer, which regulates paracellular permeability or “gut 
leakiness”; and secretory products, including the mucus lining, 
which creates physical separation between the epithelium and 
luminal contents, and IgA, which is carried along the mucus lining 
(24, 45) (Figure 1).
The intestinal epithelium consists of a single layer of highly 
specialized cells held together by more than 50 transmembrane 
tight junction (TJ) proteins (45, 46). TJ proteins form a physi-
cal barrier between the apical and basolateral epithelial com-
partments and selectively regulate passive diffusion of ions and 
water-soluble molecules through the paracellular pathway (47). 
Figure 2. Gut-brain communications through the endocrine system and 
vagus nerve. The hypothalamic-pituitary-adrenal (HPA) axis modulates 
intestinal motility (directly through urocortin production), gut microbiome 
composition, intestinal permeability, and immune system activation 
(through cortisol production). The vagus nerve influences the immune 
system through acetylcholine production and intestinal permeability and 
motility directly and through the ENS. ACTH, adrenocorticotropic hormone; 
CRH, corticotropin-releasing hormone.
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Tregs attenuate inflammatory responses and initiate immune toler-
ance (71, 72). It is thought that an imbalance between Tregs and Th17 
cells may contribute to the breakdown of immune tolerance, driving 
a number of autoimmune diseases, including MS and EAE (73–75).
The microbiota can influence activation and proliferation of 
Tregs and Th17 cells, and both GF and antibiotic-treated mice 
develop attenuated EAE (76, 77). In one study, recolonization of GF 
mice with commensal bacteria restored EAE susceptibility by pro-
moting differentiation of Th17 cells in the gut, and recolonization 
with segmented filamentous bacteria alone was enough to promote 
EAE development via stimulation of IL-17 production (75). People 
with active RRMS had significantly higher percentages of Th17 cells 
in the small intestinal mucosa compared with HCs (31). In EAE, 
MOG-specific Th17 cells migrate to the colonic LP before disease 
onset and induce dysbiosis; in this study, blocking intestinal hom-
ing of Th17 cells attenuated disease severity (78). New research has 
revealed that IL-17–/– mice have a distinct microbiota, which protects 
from EAE development. However, this protection was lost following 
transfer of microbiota from WT mice, indicating that intestinal IL-17 
production might directly influence gut microbiome composition 
and be necessary for disease development (75). In contrast, anoth-
er study found that blocking MOG-specific Th17 cells’ migration to 
the gut worsened disease severity in a mouse model of spontaneous 
EAE. This study’s authors concluded that these cells were no longer 
sequestered in the intestine and so continued to contribute to dis-
ease progression within the CNS (79).
Humoral immunity also plays a paramount role in the gut. 
Gut microbiota influence differentiation of IgA+ plasma cells 
(PCs), and IgA binding of specific bacteria was shown to influence 
gut colonization and niche formation in the human colon (80). 
Accordingly, GF mice have very low IgA levels (81). In a recent 
paper, pwMS exhibited a reduction in fecal IgA during MS relaps-
es, and IgA+ B cells were able to gain access to the inflamed CNS 
(82). IgA+ B cell removal exacerbated EAE, an outcome rescued 
by PC transfer, demonstrating their protective role (82). Moreover, 
gut microbiota–specific IgA+ B cells showed a different specificity 
in pwMS compared with HCs in another recent paper: the most 
prominent operational taxonomic units bound by IgA in pwMS, 
but not in HCs, were A. muciniphila, Eggerthella lenta, Bifidobacte-
rium adolescentis, and Ruminococcus (83).
The autonomic and enteric nervous systems
The autonomic nervous system comprises the sympathetic, para-
sympathetic, and enteric divisions, which together connect the 
gut and the CNS (84, 85). The ENS consists of neurons and gli-
al cells located in the gut smooth muscle and submucosal layers. 
These cells can regulate intestinal motility and permeability inde-
pendently of CNS inputs. Gut microbiota influence both CNS and 
ENS development, as evident in GF mice, whose myenteric plexus 
is structurally abnormal, exhibiting decreased nerve density and 
number of neurons per ganglion (86). Some neurotransmitters are 
common between the CNS and ENS, and perturbations of the ENS 
have been described in neuroinflammatory and neurodegenerative 
diseases (8, 26, 85). In a B cell/antibody-dependent EAE model, 
ENS degeneration in the myoenteric plexus was described before 
disease onset and was mediated by autoantibodies (26), which were 
also detected in a small cohort of pwMS, along with ENS gliosis (26).
when transferred in mice, Akkermansia ameliorated EAE via reduc-
tion of RORγt+ and IL-17–producing γδ T cells (64), suggesting an 
overall beneficial role similar to that observed in obesity, diabetes, 
and aging (65). Therefore, it is possible that Akkermansia’s effects 
on health and diseases are context dependent and should be consid-
ered within the specific disease setting and parallel changes of other 
bacteria and gut microbiome structure.
The intestinal immune system
The mammalian gastrointestinal tract (GIT) harbors the body’s 
greatest proportion of immune cells (66). These cells are in close 
contact with local microbiota and have the difficult task of protecting 
against pathogens while remaining tolerant toward food antigen and 
nonpathogenic commensals. The intestinal immune system compris-
es innate and adaptive immune cells, detailed extensively elsewhere 
(66, 67) (Figure 1). The microbial environment critically shapes the 
local immune system, as revealed by the vastly diminished immune 
compartment observed in the GIT of germ-free (GF) mice (67–69). In 
normal conditions, the intestinal lamina propria (LP) harbors a high 
proportion of Th17 cells (70), which protect against pathogens, while 
Figure 3. Gut-based therapies to modulate CNS autoimmunity through 
the GBA. Antibiotics, probiotics, gut-derived metabolites, fecal microbiota 
transplantation (FMT), and diet are all possible therapeutic approaches 
that could modulate CNS inflammation through the GBA. As suggested by 
preclinical and clinical studies, gut-based therapies can modify gut micro-
biota composition, which in turn modulates the production of gut-derived 
products and metabolites (e.g., LPS, SCFAs, peptidoglycan, and bile acids), 
acting on both the immune system and the CNS. Zonulin (HP2), produced 
in the small intestine, where it modulates gut barrier integrity, was sug-
gested to have a direct effect also on BBB permeability.
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again, from experiments using GF mice. GF mice exhibited exag-
gerated HPA axis activation in response to stress that was not 
reverted upon recolonization in adult mice (3). Emerging evidence 
indicates the existence of bidirectional communication between 
the neuroendocrine system and gut microbiota (98). The presence 
of gut microbiota influenced not only the physiology of the HPA 
axis but also its response to stress, possibly through the modula-
tion of vagal responses (99, 100). Altered levels of brain-derived 
neurotrophic factor (BDNF), NMDA, and 5-HT expression in the 
cerebral cortex, amygdala, and hippocampus have been described 
in GF mice (101). Several lines of evidence implicate the HPA axis 
in MS pathogenesis, MS disease progression, and occurrence of 
comorbid mood disorders (102–104). Clinical and postmortem 
studies in pwMS demonstrated elevated basal cortisol plasma 
levels, enlarged adrenal glands, higher cortisol levels in CSF, and 
increased CRH-producing hypothalamic neurons (104–106). 
Notably, low HPA axis activity was correlated with increased dis-
ease severity in pwMS (25).
Targeting the gut to modulate CNS 
autoimmunity
Animal studies clearly support the involvement of gut microbiota 
in regulating CNS inflammation, microglia functions, myelination, 
and BBB integrity (1, 2, 107). Since these processes have proven 
relevant in the pathophysiology of CNS autoimmunity, perturba-
tions of the gut microbiota and/or gut permeability are expected 
to impact the pathology and clinical course of disease in mice and 
possibly in humans. Accordingly, various interventions targeting 
gut microbiota composition and/or intestinal integrity have been 
implemented to treat CNS autoimmunity in preclinical and clinical 
studies (Figure 3). Most studies evaluating the effects of gut manip-
ulation on CNS inflammation have been performed in the EAE 
model; however, a handful of studies have used other experimental 
MS models, such as the Theiler’s murine encephalomyelitis virus 
The vagus nerve is the principal component of the parasym-
pathetic nervous system. Its afferent and efferent fibers inner-
vate the GIT and communicate directly and indirectly with the 
gut microbiota and the immune system. Vagal afferent fibers 
can sense bacterial products such as LPS and hormones (e.g., 
cholecystokinin, glucagon-like peptide-1, peptide YY) produced 
by enteroendocrine cells in response to food intake or microbial 
metabolites (87, 88). Acetylcholine (ACh), the neurotransmitter 
released by vagus efferent fibers, was shown in vitro to inhibit 
proinflammatory cytokine production in macrophages, leading to 
the “cholinergic antiinflammatory hypothesis” (89). Interestingly, 
people with RRMS have reduced ACh both in serum and cerebro-
spinal fluid (CSF), along with increased inflammatory cytokines 
IL-1β and IL-17 (90, 91). Consistent with this, increased ACh lev-
els induced by treatment with acetylcholinesterase inhibitors in 
mice with EAE resulted in suppression of T cell activation and 
decreased disease severity (92). Similarly, another study found 
that vagotomy also ameliorated EAE by inhibiting proliferation 
and differentiation of CD4+ T cells by reducing ACh and lympho-
kine secretion in the cortex (93). ACh’s seemingly contradictory 
role in regulating inflammation could reflect opposing effects of 
ACh receptors (muscarinic vs. nicotinic) expressed on immune 
cells and highlights the need for further research in the area.
The endocrine system
The endocrine system is another pathway of communication 
between the gut and the CNS (Figure 2). The HPA axis is con-
sidered a major neuroendocrine organ, regulating a multitude 
of body functions. In situations of stress, CRH, produced by the 
hypothalamus, induces the release of ACTH by the pituitary 
gland, which determines the release of corticosteroids by the adre-
nal gland (94). CRH and related hormones urocortin 1–3 influence 
intestinal motility, permeability, and immune responses (95–97). 
Evidence of a link between the GBA and HPA axes is derived, 
Table 1. Preclinical studies testing antibiotic therapy to modulate CNS autoimmunity
Animal model Intervention Results Proposed mechanisms Ref.
EAE 
SJL mice
Oral ampicillin, vancomycin, neomycin, and 
metronidazole for 7 days before EAE induction
Disease amelioration Accumulation of Tregs in peripheral lymph nodes 108
EAE 
C56BL/6 mice
Intraperitoneal ampicillin treatment in  
late-stage EAE
Disease worsening ↓ commensal bacteria capable of transforming 









Oral ampicillin, vancomycin, neomycin sulfate,  
and metronidazole starting after TMEV infection
Prevented motor disfunction, limited axon 
damage and CNS immune cell infiltration
↑ CD4+CD39+ T cells and CD5+CD1d+ B cell 
populations in the CNS and decreased IL-17 




Oral norfloxacin and Clostridium butyricum  
(C. butyricum) for 7 days before EAE induction
Disease amelioration ↓ Firmicutes/Bacteroidetes ratio and Th17, while 





Oral treatment with antibiotic mix for 12 weeks 
before lysolecithin
↑ inflammatory activation of infiltrating 
macrophages and resident microglia; impaired 
myelin debris clearance and OPC differentiation
Altered gut microbiota composition 114
EAE 
C57BL/6 mice
Oral ampicillin, vancomycin, neomycin,  
or metronidazole or a combination of these  
1 week before immunization
Prevented demyelination in the spinal cord Depleted gut microbiome and decreased number 
of MOG-specific T cells
109
AHR, aryl hydrocarbon receptor; OPC, oligodendrocyte precursor cell. 
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(TMEV) model and toxin-induced models of CNS demyelination. 
Tables 1, 2, 3, and 4 summarize preclinical and clinical studies tar-
geting the gut to modulate CNS autoimmunity.
Antibiotic treatment. Antibiotic treatment has been shown to 
ameliorate EAE through effects mediated via the gut microbiota 
(30, 77, 108–110). Seminal work demonstrated that oral treatment 
with broad-spectrum antibiotics significantly altered the gut flora 
and reduced EAE severity in a Treg-dependent manner (108). Dis-
ease amelioration did not occur when antibiotics were given intra-
peritoneally, thereby bypassing the gut, suggesting that modulation 
of the gut microbiota produces protective effects. Similarly, Yokote 
and colleagues reported that antibiotic treatment protected mice 
from EAE but found invariant NK T cells as the key drivers (77). A 
recent report found that oral treatment with ampicillin decreased 
EAE severity and identified two molecules produced by L. reuteri 
and a newly isolated strain from the Erysipelotrichaceae family, 
which act synergistically to induce accumulation of MOG-specif-
ic Th17 cells in the small intestine (109). Further, several studies 
have reported that treatment with antibiotics before EAE induction 
or at presymptomatic stages, but not after disease onset, protect-
ed mice from disease (30, 110, 111). Antibiotics administered at a 
presymptomatic phase also protected from motor dysfunction in 
TMEV-infected mice, another animal model of MS (112). Indeed, 
one study reported that ampicillin treatment during clinical EAE 
worsened the disease, whereas vancomycin treatment exerted no 
clinical effect (113). Effects of antibiotic treatment were also stud-
ied in the lysolecithin-induced model of CNS demyelination. In 
this study, antibiotic treatment before injection of the toxic com-
pound into the spinal cord resulted in increased immune response 
14 days after demyelination induction, with impaired debris clear-
ance, without affecting remyelination (114).
Studies focusing on the effects of antibiotic treatment in 
pwMS are scarce. Two small studies investigating the effects of 
doxycycline combined with IFN-β in pwMS reported decreased 
relapse rates, improved measures of disability, and reduced gad-
olinium-enhancing lesions compared with IFN-β treatment alone 
(115, 116). Another randomized, double-blind placebo-controlled 
study showed that minocycline delayed the conversion of people 
with CIS to MS over a 6-month but not 24-month period (117). 
A larger study on people with CIS is ongoing (ClinicalTrials.gov 
NCT04291456).
In summary, EAE studies suggest that antibiotic treatment has 
beneficial effects when administered preventatively but not once 
disease is established. Mechanisms mediating antibiotics’ effects 
are not understood but likely are due to microbial modulation, 
which may in turn alter immune activation (111, 118). Long-term 
antibiotic therapy in pwMS shows promising results but carries 
risks, such as promoting the growth of opportunistic pathogens, 
including Clostridium difficile (C. difficile), fungi, and antibiot-
ic-resistant infections (119). Furthermore, the possibility of direct 
side effects, such as dental discoloration, rash, and photosensitivi-
ty with minocycline treatment (117), must also be considered.
Probiotic supplementation. Probiotics have gained much inter-
est recently as potential therapeutic agents in MS. These live 
microorganisms are believed to exert their effects by modulat-
ing the gut flora to one that promotes intestinal barrier integri-
ty and differentiation and activation of immunoregulatory over 
inflammatory cell subsets (120, 121). Probiotic administration in 
rodents with EAE has focused mainly on the effects of Lactobacil-
lus strains, either alone or in combination with other strains (122–
128). Most studies report an attenuation of EAE clinical course, 
but results are inconsistent and often contradictory. Herein we 
Table 2. Preclinical studies testing probiotic supplementation to modulate CNS autoimmunity
Animal model Intervention Results Proposed mechanisms Ref.
EAE 
C57BL/6 mice
Oral administration of a Lactobacilli mix  
12 days before immunization
Disease amelioration ↓ CNS infiltration by CD4+ T cells and production  
of IFN-γ and TNF-α. 









Treatment with Lactobacillus (L. plantarum)  
and Bifidobacterium animalis (B. animalis)  
starting at EAE induction
Disease amelioration ↓ CNS infiltration and increased the number of Tregs  




Oral administration of E. coli Nissle 1917  
after EAE induction
Disease amelioration ↓ migration of MOG-reactive T cells into the CNS. 




Monocolonization of GF mice with  
Prevotella diastonis (P. diastonis)






Oral treatment with Prevotella histicola  
(P. histicola)
Suppressed EAE development ↑ levels of IL-10 and TGF-β. 
↓ production of IL-17 and IFN-γ by splenocytes  




Intraperitoneal treatment with Lactobacillus helveticus  
starting 3 weeks before immunization
Disease amelioration ↓ Th17 in the peripheral lymph nodes and their 




Oral Lactobacillus reuteri (L. reuteri) starting  
at immunization





Cocolonization of GF mice with L. reuteri  
with a novel strain of Erysipelotrichaceae
Worsened disease: amplified MOG 
response
Molecular mimicry between the uvrA gene product  
of L. reuteri and MOG
109
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discuss some of the main published studies, mindful that this is 
not a comprehensive review of the literature on this topic (121). 
Daily oral administration of a mixture of Lactobacillus strains in 
EAE was effective both at preventing disease development and 
reversing established disease, an outcome that was IL-10 depen-
dent and correlated with Treg induction in mesenteric lymph 
nodes and the CNS (125). Similarly, treatment with a mixture of 
L. plantarum of human origin and B. animalis attenuated EAE 
clinically and induced Tregs in lymph nodes and spleen (124). 
Oral administration of human-derived L. reuteri after immuniza-
tion ameliorated EAE with a decrease in Th1/Th17 subsets and 
related cytokines (122). In contrast, a recent study showed that 
L. reuteri administration amplified MOG-specific responses in GF 
mice monocolonized with a novel strain of the Erysipelotricha-
ceae family (109). The molecular similarity observed between 
MOG and the uvrA gene product of L. reuteri was advocated as 
the possible mechanism mediating EAE exacerbation (109). 
Similarly, another study found that L. reuteri exacerbated EAE 
in genetically susceptible mice (129). Such conflicting findings 
may result from L. reuteri’s interaction with other commensal 
microbes present and their combined impact. Besides Lactobacil-
lus strains, other gut bacteria given orally have been associated 
with probiotic effects and EAE amelioration, such as C. butyricum 
(30), E. coli strain Nissle 1917 (59), and P. histicola (130). Admin-
istration of a mixture of probiotics (Streptococcus, Bifidobacterium, 
and Lactobacillus strains) was also tested in the TMEV infection 
model, with beneficial effects of decreased CNS inflammation 
and increased motor activity during the disease (131).
Human studies are scarce, and treatment with a probiotic mix 
has only been tested in three studies involving pwMS (132–134). 
In two small double-blinded randomized controlled trials (RCTs), 
pwMS who received a mix of Lactobacillus and Bifidobacterium 
daily for 12 weeks showed significant improvements in disability 
score, depression, anxiety, and inflammatory markers, including 
reduced IL-8 and TNF-α expression in PBMCs (132, 133). Similarly, 
Tankou and collaborators administered a probiotic mix containing 
Lactobacillus, Bifidobacterium, and Streptococcus to pwMS and HCs 
twice daily for 2 months and found reduced CD80 expression on 
peripheral monocytes. The described changes in gut microbiota 
composition and the immune system were not maintained after 
probiotic discontinuation, thus suggesting the necessity of contin-
uous supplementation (134).
In summary, research into probiotic supplementation in EAE 
and MS remains inconclusive and rigorous clinical trials are lacking. 
Results may be affected by dosage, duration, and type of bacterial 
strains; host genotype; immune status; and endogenous microbiota. 
Nevertheless, probiotic supplements are currently widely used by 
pwMS (121). A clinical study evaluating the effect of probiotic mix 
on patients with MS and CIS is ongoing (NCT04038541).
Products derived from the gut microbiota. Preclinical and clinical 
investigations into the therapeutic potential of microbial products, 
particularly SCFAs, are currently ongoing. Increase in SCFA levels is 
commonly achieved through either high-fiber diet or direct SCFA sup-
plementation (135). While SCFA supplementation has shown efficacy 
in reducing EAE clinical severity and inflammation, high-fiber diet 
produces more varying results (20, 136, 137). Park and collaborators 
Table 3. Preclinical studies testing SCFA supplementation, FMT, and diet modifications to modulate CNS autoimmunity
Intervention Animal model Intervention Results Proposed mechanisms Ref.
SCFA EAE 
C57BL/6 mice
Supplementation with LCFAs or SCFAs  
at immunization or at disease onset
Treatment with LCFAs exacerbated and 
treatment with SCFAs ameliorated EAE





Oral administration of SCFAs for 3 weeks 
before immunization
Disease amelioration ↑ proportion of Tregs in the spleen 




Oral administration of SCFAs for 2–4 weeks 
before immunization
Disease amelioration ↓ expression of proinflammatory 
cytokines 
↑ expression of IL-10 in the spinal cord
20
FMT SJL mice (spontaneous  
RR model)
Colonization with microbiota obtained  
from twins discordant for MS
Disease worsening  
(microbiota from MS patients)





Colonization with microbiota from  
pwMS 6 weeks before immunization





Oral treatment with miR-30d after  
EAE onset
Disease amelioration ↑ CD4+FoxP3+ T cells and MOG-specific 
Tregs in the spleen
36
Diet modification EAE 
C56BL/6 mice
IF started before or on the day of 
immunization
Prevented or ameliorated EAE N/A 150
EAE 
C56BL/6 mice
IF regimen started 4 weeks before 
immunization
Disease amelioration Altered microbiome composition 
↓ serum leptin and ↑ adiponectin 




Tryptophan-free diet started  
at the day of immunization
Prevented EAE ↓ MOG-reactive CD4+ T cells 





Methionine restriction started 2 weeks  
prior to immunization
Disease amelioration ↓ the expansion of Th17 cells 154
IF, intermittent fasting; LCFA, long-chain fatty acid; RR, relapsing-remitting.
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A recent clinical trial tested the effects of propionate supple-
mentation for 2 weeks, as an add-on therapy in 91 pwMS and 24 
HCs. Propionate lowered Th17 cells and increased Tregs and their 
in vitro suppressive capacity in an IL-10–dependent manner, and 
the effects were more pronounced in pwMS (21). Longitudinal 
data in 97 pwMS who underwent propionate supplementation 
for at least 1 year showed similar immunological changes, with a 
decrease in annualized relapse rate, disability stabilization, and a 
decrease in brain atrophy (21).
Besides SCFAs, other gut-derived metabolites have been stud-
ied as possible modulators of neuroinflammation. Bhargava and 
collaborators recently demonstrated that TUDCA administration 
reduced EAE clinical severity and could modulate astrocyte and 
unveiled a possible dual role of SCFAs during CNS inflammation, 
whereby supplementation with a mix of propionate, butyrate, and 
acetate dampened EAE by increasing IL-10–producing T cells, but 
also induced inflammatory T cells through the GPCRs GPR41 and -43 
(20). Additionally, propionate supplementation before EAE induc-
tion, but not at disease onset, ameliorated disease and increased Tregs 
in the intestinal LP (136). In the cuprizone model of CNS demyelin-
ation, butyrate treatment for 1 week before commencing toxin admin-
istration decreased demyelination and enhanced remyelination 
(138). Administration of an SCFA mix via drinking water in GF mice 
in steady-state conditions rescued microglia defects associated with 
the absence of gut microbiota and gut-derived metabolites similarly 
to that observed in GF mice recolonized with live gut bacteria (139).
Table 4. Clinical trials testing gut-based therapies in pwMS
Intervention Ref. Study details Results
Antibiotics 115 Open-label trial: n = 15 pwMS with breakthrough disease activity were treated 
with IFN-β1a and 100 mg of doxycycline daily for 4 months
Improved EDSS score and reduced gadolinium-enhancing lesions at MRI
116 Double-blind clinical trial: n = 60 pwMS with breakthrough disease were treated with 
44 μg subcutaneous IFN-β1a 3 times a week or 30 μg intramuscular IFN-β1a once a 
week plus 100 mg of doxycycline daily for 6 months
↓ relapse rate and improved EDSS score
117 Randomized placebo-controlled study: n = 142 subjects diagnosed with CIS 
assigned to receive either minocycline or placebo for 24 months
↓ risk of conversion to MS at 6 months
Probiotics 132 Randomized double-blind, placebo-controlled study: n = 60 (30/group) 
pwMS (18–55 years of age) with EDSS ≤ 4.5 receiving a probiotic mixture 
containing Lactobacillus acidophilus (L. acidophilus), Lactobacillus casei (L. casei), 
Bifidobacterium bifidum (B. bifidum), and Lactobacillus fermentum (L. fermentum) 
(each 2 × 109 CFU/g) for 12 weeks
Improved plasma levels of CRP, nitric oxide metabolites, and MDA 
↓ serum insulin and ameliorated insulin resistance parameters 
Improved EDSS, Beck depression inventory, general health questionnaire, 
and depression anxiety and stress scale 
133 Randomized, double-blind, placebo-controlled clinical trial: n = 40 pwMS assigned 
to receive either L. acidophilus, L. casei, B. bifidum, and L. fermentum (2 × 109 CFU/g 
each; n = 20) or placebo (n = 20) for 12 weeks
↓ expression of IL-8 and TNF-α in PBMCs
168 Case-control study: n = 9 RRMS patients and 13 HCs treated with oral LBS 
(4 strains of Lactobacillus, 3 strains of Bifidobacterium, and 1 strain of 
Streptococcus) twice daily for 2 months
Changes in the overall microbial community structure 
↓ abundance of several KEGG pathways 
↓ frequency of intermediate monocytes 
↓ expression of HLADQA1 and proinflammatory genes in peripheral monocytes
Gut-derived 
bacterial products
21 n = 179 pwMS and 68 HCs received oral propionic acid for 14 days ↑ Treg induction and enhancement of Treg function 
Imbalance between Treg and Th17 cells in pwMS was restored
FMT 142 Case report on 1 SPMS (EDSS 6) patient receiving an FMT. Ten-year follow-up EDSS score stabilized
141 Single-arm, nonrandomized, time series, single-subject study ↑ Firmicutes/Bacteroides and Prevotellaceae/Bacteroides ratio 
↑ abundance of Faecalibacterium prausnitzii (F. prausnitzii) 
↑ SCFA-genomic pathway 
↑ serum BDNF levels 
Ameliorated gait metrics 
Dietary restriction
Dietary restriction 143 Randomized, double-blind, placebo-controlled clinical trial: n = 60 participants 
assigned to ketogenic diet (n = 20), fasting mimicking diet for 7 days followed by 
Mediterranean diet (n = 20), or control (n = 20) for 6 months
Well tolerated 
↑ in MS-related quality of life 
↓ disability
151 Prospective cross-sectional study: n = 218 RRMS patients who were able to fast 
during Ramadan
↑ cognitive domain score at the MFIS and physical and mental health 
composites at the QOL scores
152 Randomized, double-blind, placebo-controlled clinical trial: n = 36 RRMS 
randomly assigned to daily caloric restriction, intermittent caloric restriction,  
or control for 8 weeks
Weight loss 
↑ emotional well-being
144 Randomized, double-blind, placebo-controlled clinical trial: n = 17 RRMS, 
enrolled during a relapse, randomly assigned to IF or control for 15 days
Weight loss 
↓ leptin and modulated gut microbiome composition
CIS, clinically isolated syndrome; CRP, C-reactive protein; KEGG, Kyoto Encyclopedia of Genes and Genomes; MDA, malondialdehyde; MFIS, Modified 
Fatigue Impact Scale; QOL, quality of life; SPMS, secondary progressive MS.
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tion, as recently reviewed (148). Several clinical trials in pwMS also 
tested DR, reporting positive effects on measures of fatigue and 
emotional health (143, 151, 152). In an RCT, 15 days of intermit-
tent energy restriction versus ad libitum diet in 16 pwMS having 
a relapse was well tolerated and reduced levels of the proinflam-
matory adipokine leptin without altering levels of adiponectin. In 
this study, DR effects on the gut microbiota included enrichment 
of Faecalibacterium, Lachnospiraceae incertae sedis, and Blautia (all 
bacteria associated with immunomodulatory effects) while Faeca-
libacterium was strongly correlated with adiponectin levels (144). 
A longer trial in a larger cohort of pwMS is currently ongoing (Clin-
icalTrials.gov NCT03539094).
Modification of diet composition also modifies the gut micro-
biota and has been shown to interfere with CNS autoimmunity. As 
mentioned above, high-fiber diet can promote SCFA production 
by the gut microbiota. A clinical trial analyzing the effects of high 
fiber supplementation in a cohort of pwMS is ongoing (ClinicalTri-
als.gov NCT04574024). A recent study demonstrated that elimi-
nating dietary tryptophan can produce a protective effect in EAE. 
Dietary tryptophan is necessary to prime MOG-reactive T cells to 
induce EAE, and a tryptophan-free diet is sufficient to completely 
prevent the disease (153). Interestingly, a group of vancomycin-re-
sistant commensal bacteria, including L. reuteri, could catalyze 
the conversion of dietary tryptophan into AHR agonists capable 
of crossing the BBB, suppressing astrocytic inflammatory profiles 
and improving EAE (113). In another recent study, dietary methi-
onine restriction resulted in impaired CD4+ T cell activation and 
protection against EAE, since methionine is a critical component 
for Th17 cell proliferation and differentiation (154).
Targeting epithelial integrity. Studies focusing on possible ther-
apeutic strategies to target epithelial integrity in MS or its animal 
model are lacking. However, in other inflammatory diseases, this 
approach seems promising. For instance, phosphatidylcholine 
constitutes a large proportion of phospholipids in the mucus lay-
er of the intestine. Small studies on ulcerative colitis showed how 
phosphatidylcholine supplementation was more effective than 
placebo in reaching clinical remission through enhancing barrier 
integrity (155). While this remains untested in patients with MS, it 
provides a potential area to be explored.
Effects of current MS treatments on the GBA
Disease-modifying treatments (DMTs) and immunosuppressive 
drugs currently used to treat MS can have some effects on the GBA 
(Figure 1). Therapy-induced changes in the gut microbiota (e.g., 
favoring microbes with antiinflammatory properties) could possibly 
contribute to their clinical efficacy, even though these aspects have 
not been well investigated. A recent cross-sectional study analyzed 
the effects of glatiramer acetate (GA) and DMF in 168 pwMS; while 
they did not change the overall microbial community structure com-
pared with untreated pwMS, both impacted the abundance of several 
genera, with the most significant effect of DMF being on the order 
of Clostridiales (156). In contrast, a pilot study using delayed-release 
DMF found no statistically significant effects on the gut microbiota 
(157). Other studies also reported changes in gut microbiota compo-
sition after GA or IFN-β treatment, such as increased abundance of 
the genera Prevotella and Sutterella, with overall effects that tended to 
normalize some of the alterations observed in pwMS compared with 
microglia polarization in vitro (19). To the best of our knowledge, 
studies testing bile acids in humans have not been published yet, 
but an ongoing RCT is evaluating safety and tolerability of TUDCA 
in people with progressive MS (ClinicalTrials.gov NCT03423121).
To conclude, initial studies on SCFA supplementation are 
promising. While there are no known side effects, adherence to 
supplementation is impaired by butyrate’s poor palatability. How-
ever, more randomized studies testing SCFAs or other gut bacteri-
al products in pwMS are necessary to draw any conclusion.
Fecal microbiota transplantation. Given the condition of dys-
biosis observed in pwMS, FMT has been proposed as a possible 
approach to reestablish a balanced gut microbiota. In EAE, FMT 
from naive into immunized mice resulted in reduced microglia 
and astrocyte activation, lower BBB leakage, and reduced demy-
elination and axonal loss (140). In a case study, a patient with MS 
who received daily FMTs from five donors displayed increased 
relative abundance of F. prusnitzii and levels of propionate, butyr-
ate, and BDNF and decreased proinflammatory cytokines in the 
weeks following the transplant. Clinically, the patient demonstrat-
ed an improvement in balance and walking capacity (141). Anoth-
er report described clinical stability during a 10-year follow-up in 
a patient with secondary progressive MS who underwent an FMT 
procedure to treat recurrent C. difficile infections (142).
In summary, there is insufficient evidence to suggest a 
clinical benefit of FMT in pwMS, and several clinical trials are 
ongoing (ClinicalTrials.gov NCT04096443, NCT03594487, 
NCT04150549). Difficulties in implementing this approach arise 
from lack of consensus on variables such as donor selection, fecal 
matter processing, route of administration, recipient premedica-
tion, and frequency of transplant. Such variables also create chal-
lenges when comparing outcomes from different studies.
Diet. Manipulating calorie intake and diet composition is 
another way to modulate CNS autoimmunity through chang-
ing gut microbial ecology and possibly other GBA components. 
Dietary interventions such as dietary restriction (DR), ketogenic 
diet, high-fiber and high-fat diets (143–146), and Paleolithic diet 
(147) have been tested in MS models and pwMS, but each diet’s 
effects on gut microbiota have not been extensively investigated. 
DR, defined as the chronic or intermittent reduction of calorie 
intake without malnutrition, has antiinflammatory effects and can 
ameliorate EAE through multiple mechanisms, including effects 
on the gut microbiota (148). Chronic or intermittent DR increases 
gut microbiota richness and alters its composition, as extensively 
reviewed recently (148). Lifelong DR in mice is known to change 
gut microbiota structure with enrichment of antiinflammatory 
bacteria strains, such as the genus Lactobacillus, accompanied 
by reduced serum proinflammatory endotoxin load from the gut 
(149). IF (24-hour fasting-feeding cycles) prior to disease induc-
tion leads to EAE attenuation, which is associated with changes 
in gut microbiota richness and composition (144, 150). Notably, 
disease protection is transferred by gut microbiota transplantation 
from IF mice into newly immunized recipients, suggesting the 
role of the gut microbiota in mediating DR’s beneficial actions in 
EAE (144). DR could also act on other GBA components by acti-
vating the endocrine (e.g., increasing steroid hormone levels) and 
autonomic (e.g., activating the parasympathetic system) systems, 
which could contribute to its effects in reducing neuroinflamma-
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more research is needed to better clarify molecular pathways con-
necting gut and brain functions and how they impact CNS auto-
immunity. Interventions including FMT, probiotics, antibiotics, 
and diet that modulate the GBA have been actively investigated 
in preclinical models and to some extent also in clinical settings. 
Despite promising immunomodulatory effects of these therapies, 
only limited data exist on their impacts on neurodegenerative 
disease mechanisms. Nevertheless, we believe that in the future, 
therapies targeting the gut microbiota may be beneficial as an 
add-on treatment to already approved DMTs because they could 
potentially act synergistically. Some of these gut-based approach-
es (e.g., probiotic supplements) are already often implemented 
by pwMS because they are easily accessible as over-the-counter 
medications. While they do not have major side effects, the lack of 
appropriate regulatory organizations to control different prepara-
tions underlines the necessity for more controlled studies.
Looking ahead, microbiome-associated therapeutics will like-
ly serve as an important component for precision medicine in MS. 
This will require a comprehensive understanding of patients’ dis-
tinct gut microbial composition and function and thorough char-
acterization of microbial interaction with the host immune system 
and other GBA components. This novel approach could also assist 
in monitoring response to treatments and may greatly benefit peo-
ple suffering from this debilitating disease.
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HCs (13, 15). In EAE, the immunomodulatory effect of type I IFNs on 
CNS autoimmunity was linked to the induction of the transcription 
factor AHR, which was subsequently activated by microbially derived 
metabolites of tryptophan and resulted in antiinflammatory effects 
within the CNS. However, this study did not demonstrate a direct 
effect of treatment with type I IFNs on gut microbiota composition 
(113). Notably, both fingolimod and IFN-β have gut barrier–stabiliz-
ing properties by promoting intestinal barrier integrity, partly by reg-
ulating TJ proteins (55, 158). Natalizumab, an anti–α4 integrin mAb, 
modulates lymphocyte trafficking and inflammation across both the 
BBB and gut epithelia and has been shown to reduce the severity of 
inflammatory bowel disease (159).
Immunosuppressive drugs could affect the gut microbiota’s 
function and composition. In nonhuman primates, alterations 
in gut microbiota composition and the immune system were 
described after treatment with alemtuzumab. Alemtuzumab 
induces profound systemic lymphocyte depletion that is also 
observed at the intestinal level (160). Lymphocyte depletion is 
associated with decreased abundance of Lactobacillus species and 
Weissella cibaria, decreased fungal diversity, and expansion of spe-
cific phylotypes, including Candida albicans (161, 162).
Steroids are commonly used to treat MS symptoms during a 
relapse, but little is known about the effect of steroid treatment on 
gut microbiota in pwMS. In mice, short- and long-term treatment 
with dexamethasone increased the abundance of Actinobacteria, 
Bifidobacterium, and Lactobacillus (163). As underlined above, pwMS 
show an overactivation of the HPA axis with higher levels of cortisol 
in the CSF compared with HCs (25). The activation of the HPA axis, 
associated with increased cortisol levels, can alter gut permeability, 
increasing circulating levels of immunostimulatory molecules (164).
Symptomatic treatments, such as drugs used for motor and/or 
psychiatric symptoms in pwMS, may also influence gut microbiota 
composition and could contribute to clinical efficacy. For exam-
ple, antidepressant use can alter gut microbiota composition both 
directly and indirectly through modulation of neurotransmitter 
levels. The potential antimicrobial activity has been demonstrat-
ed for various classes of antidepressant drugs, such as tricyclics 
and selective serotonin reuptake inhibitors (165, 166), although 
the exact effect on gut flora composition is not clear. Similarly, a 
drug combining delta-9-tetrahydrocannabinol and cannabidiol, 
which is commonly used to treat muscle spasticity in pwMS, has 
been shown to reduce the levels of proinflammatory cytokines and 
the relative abundance of A. muciniphila in EAE (167).
Conclusions
Rapidly growing evidence supports the GBA’s role in MS patho-
genesis, with the gut microbiome as a critical player. However, 
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